Medivation's Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimer's...

Medivation's Dimebon(TM) Significantly Improved Thinking and Memory in
Alzheimer's Disease Patients Over One Year
- Cognitive Function Data from Pivotal Trial Presented at American Academy of
Neurology 60th Annual Meeting -

SAN FRANCISCO and CHICAGO, April 17 /PRNewswire-FirstCall/ -- Medivation,
Inc. (Nasdaq: MDVN) today announced that Alzheimer's patients treated with the
investigational drug Dimebon(TM) showed improvement in the key aspects of
cognitive function over a one-year period compared with placebo. The
improvement occurred in not only memory and language, but also in more complex
functions such as awareness of time and place, and praxis -- the process of
getting an idea and initiating and completing a new motor task. These
clinical results were generated during a pivotal trial of Dimebon in patients
with mild-to-moderate Alzheimer's disease (AD).
The data were presented today during an oral presentation at the 60th
Annual Meeting of the American Academy of Neurology (AAN) by Steven H. Ferris,
Ph.D., the Gerald J. and Dorothy R. Friedman Professor of Psychiatry at New
York University and director of the NYU Alzheimer's Disease Center.
"The finding that Dimebon improved memory, orientation, language and
praxis in Alzheimer's disease patients suggests that it provides a broad
rather than a selective cognitive benefit," said Dr. Ferris. "This is an
important finding given that deficits in memory and thinking are one of the
hallmarks of Alzheimer's disease and cause patients and caregivers significant
distress."
Dimebon Significantly Improved Cognitive Function at One Year
The data presented at the AAN Annual Meeting included results of an
analysis of the 11 subdomains of the Alzheimer's Disease Assessment
Scale-cognitive subscale (ADAS-cog), a standardized measure of cognition in
patients with AD and one of two endpoints the U.S. Food and Drug
Administration (FDA) has used to approve all currently marketed drugs for
mild-to-moderate AD. In the study, ADAS-cog was assessed at the beginning of
the study and at weeks 12, 26, 39 and 52.
Results showed that Dimebon-treated patients were significantly improved
compared with placebo on 9 of the 11 ADAS-cog subdomains after one year of
treatment. Benefits were observed in memory (word recall, p=0.04; word
recognition, p=0.03; remembering instructions, p=0.10); orientation (p= 0.01);
constructional praxis (the ability to copy simple drawings or patterns,
p=0.005) and ideational praxis (the ability to perform a familiar but complex
sequence of actions, p=0.006); and language (following commands, p<0.0001;
naming objects, p<0.0001; word finding, p=0.005; comprehension, p=0.15;
overall language, p=0.0002).
"We have recently presented a number of different findings from our first
pivotal trial of Dimebon at scientific conferences, demonstrating that this
investigational drug has a beneficial impact on the key aspects of Alzheimer's
disease -- from behavioral symptoms to thinking and memory problems to
impairments in daily function," said Lynn Seely, M.D., chief medical officer
of Medivation. "Medivation is committed to rapidly developing Dimebon as a
treatment for mild-to-moderate Alzheimer's disease to make it available to the
millions of people who suffer from this increasingly prevalent disease, for
which new treatment options are desperately needed."
Dimebon Showed Statistically Significant Benefit Versus Placebo on All Key
Efficacy Endpoints
Medivation previously announced efficacy and safety results from the
pivotal, 12-month, double-blind, placebo-controlled trial of Dimebon in 183
patients with mild-to-moderate AD. Dimebon improved the clinical course of
Alzheimer's disease patients by causing statistically significant improvements
over placebo in each of the five primary aspects of the disease -- memory,
thinking, activities of daily living, behavior and overall clinical function.
Significant gains over placebo were evident after as little as 12 weeks of
treatment, and were maintained after both six months and a full year of
treatment. In addition, after six months of treatment, Dimebon patients were
significantly better on all five disease aspects than they were at the
beginning of the study. The real-world impact of these data was evaluated by
independent assessment, including caregiver interviews, which confirmed
improvement or stabilization in 81 percent of Dimebon-treated patients after
six months of treatment. Importantly, Dimebon's overall benefit compared to
placebo continued to increase over time, and was larger at one year than at
six months.
Dimebon was well-tolerated throughout the entire one-year treatment
period. The majority of adverse events were mild, with dry mouth (18.0 percent
Dimebon, 1.1 percent placebo) and depressed mood the most common events.
There were significantly fewer serious adverse events in the Dimebon group
than in the placebo group at one year.
Medivation is planning to initiate a second, confirmatory pivotal Phase 3
trial of Dimebon in mild-to-moderate AD in the second quarter of 2008 with the
goal of completing the trial and applying for U.S. and European marketing
approval in 2010. The Company is also evaluating Dimebon in an ongoing
Phase 2 clinical trial in mild-to-moderate Huntington's disease. Dimebon is
an orally-available small molecule that has been shown to inhibit brain cell
death in preclinical models relevant to Alzheimer's and Huntington's diseases,
making it a potential treatment for these and other neurodegenerative
diseases.
About Medivation
Medivation, Inc. is a biopharmaceutical company with small molecule drugs
in clinical development to treat three large, unmet medical needs --
Alzheimer's disease, Huntington's disease and hormone-refractory prostate
cancer. The Company's strategy is to identify promising product candidates,
to develop them in a rapid, cost-effective manner, and to seek development
and/or commercialization partners as appropriate to complement its internal
efforts. For more information, please go to http://www.medivation.com.
This press release contains forward-looking statements, including
statements regarding anticipated clinical and regulatory milestones, which are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements involve risks and
uncertainties that could cause actual results to differ significantly from
those projected. You are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date of this release.
None of the Company's product candidates has been approved for sale,
significant additional animal and human testing is required in order to seek
marketing approval for any of its product candidates, and Medivation cannot
assure you that marketing approval can be obtained for any of its product
candidates. Furthermore, as is typically the case at this stage of the
regulatory review process, the FDA has not yet performed an in-depth review of
Medivation's preclinical and clinical data, so its views remain subject to
change. Medivation's filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-KSB for the year ended December 31,
2007, include information about additional factors that could affect the
Company's financial and operating results.
SOURCE Medivation, Inc.

Patrick Machado, Chief Financial Officer of Medivation, Inc., +1-415-829-4101;
or Amanda Mason of WeissComm Partners, +1-646-382-3820, for Medivation, Inc.